Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report


Cakmak M. E., KAYA S. B., CAN BOSTAN Ö., TUNCAY G., DAMADOĞLU E., KARAKAYA G., ...More

ASTIM ALLERJI IMMUNOLOJI, vol.18, pp.27-29, 2020 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 18
  • Publication Date: 2020
  • Doi Number: 10.21911/aai.584
  • Journal Name: ASTIM ALLERJI IMMUNOLOJI
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.27-29
  • Keywords: COVID-19, asthma, omalizumab, severe allergic asthma, anti-IgE, INFECTIONS
  • Hacettepe University Affiliated: Yes

Abstract

Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world. SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases. There are concerns that COVID-19 will be more severe in patients with severe asthma. The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown. In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19. To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma.